INVEGA® SUSTENNA® is an appropriate therapy option for many patients over the age of 18 in need of treatment of schizophrenia1

Patients can be transitioned to
INVEGA® SUSTENNA® directly from any
oral antipsychotic1:

  • Before starting INVEGA® SUSTENNA®, tolerability should be established with oral paliperidone or oral risperidone if a patient has not taken oral paliperidone or oral or injectable risperidone in the past.1
  • In clinical trials with INVEGA® SUSTENNA®, patients without previous exposure to paliperidone or risperidone received 3 mg to 6 mg/day of oral paliperidone.1

Previous oral antipsychotics can be discontinued at the time of initiating INVEGA® SUSTENNA®.1

There are no systematically collected data to specifically address switching from other antipsychotics to INVEGA® SUSTENNA®.1

INVEGA® SUSTENNA® is available in a range of doses1

IM injection sites and needles for monthly maintenance
injections

117 mg is the recommended monthly maintenance dose for
INVEGA® SUSTENNA®1

Some patients may benefit from lower or higher doses within the recommended range of 39 mg to 234 mg, based on individual patient tolerability and/or efficacy1

  • INVEGA® SUSTENNA® is dosed to rapidly achieve therapeutic paliperidone concentrations—no need for oral supplementation1
  • INVEGA® SUSTENNA® 39-mg/78-mg, 117-mg, and 234-mg maintenance doses injected once-monthly provide steady-state exposure similar to 3-mg, 6-mg, and 12-mg daily doses of oral INVEGA® (paliperidone) extended-release tablets, respectively1
  • Each injection should be administered by a healthcare professional. Administration should be in a single injection. Do not administer the dose in divided injections. Do not administer intravascularly or subcutaneously1
  • For intramuscular injection only. Care should be taken to avoid inadvertent injection into a blood vessel1

What do I do if a patient misses the second initiation dose?

If your patient misses a second initiation dose of INVEGA® SUSTENNA®, please see the chart below. The recommended reinitiation depends on the length of time that has elapsed since the patient’s first injection.1


Missed maintenance dose of
INVEGA® SUSTENNA®?

If your patient misses a maintenance dose of INVEGA® SUSTENNA®, please see the chart below.1


Dosing Guide
CHA-IVS-F14487

Missed monthly maintenance dose

Dosing schedule

1 month to 6 weeks late

Resume regular monthly dosing as soon as possible at patient's previously stabilized dose

>6 weeks to 6 months late

 

Continue dosing at patient's previously stabilized dose* by giving:

  1. Deltoid injection as soon as possible

  2. Deltoid injection 1 week later at same dose

  3. Patient's previously stabilized dose in deltoid or gluteal muscle

1 month after second dose.

 

*If patient was stabilized on 234 mg, the first 2 doses should be 156 mg.

>6 months late

Restart dosing with normal initiation plan:

  1. 234-mg deltoid injection at Day 1

  2. 156-mg deltoid injection 1 week later

  3. Patient's previously stabilized dose in deltoid or gluteal muscle

1 month after second dose

 

Intramuscular injection of
INVEGA® SUSTENNA®

Because intramuscular injection options are available for INVEGA® SUSTENNA®, keep in mind that, depending on your patient’s weight or where he or she would prefer to get his or her injection, a different-sized needle should be used.1

  • No Z-track administration method required1
  • Initiation doses must be administered in the deltoid muscle. Maintenance doses may be administered via either the deltoid or gluteal muscle. Gluteal administration should be made into the upper-outer quadrant of the gluteal area. Injections, both deltoid and gluteal, should be alternated between the left and right sides of the body1
  • Care should be taken to avoid inadvertent injection into a blood vessel1

IM injection sites and needles for monthly
maintenance injections